Brain Tumour Awareness Month, observed in May, serves to increase public awareness of the complexities associated with brain tumour diagnosis, treatment, and the essential need for augmented research efforts. The impact on patient health is profound, with cancerous brain tumours having a five-year survival rate of approximately 35%, and glioblastoma multiforme (GBM), the most prevalent type of cancerous brain tumour, having a mere 7% five-year survival rate. While up to 70% of brain tumours are non-cancerous, they still pose substantial health risks and can be life threatening, underscoring the necessity for effective diagnosis and treatment, according to GlobalData, a leading data and analytics company.

GlobalData estimates that 625,000 new cases of brain tumours are diagnosed each year, with 70,000 of those cases occurring in the US. Symptoms such as headaches, seizures, and changes in personality can indicate the presence of a tumour. Early detection is crucial in reducing the risk of life-altering complications and improving treatment outcomes.

Ashley Clarke, Medical Analyst at GlobalData, comments: “The recent advancements in diagnostic imaging, including AI and specialized contrast agents, have significantly enhanced tumour cell identification. Functional MRI and diffusion tensor imaging provide valuable insights into tumour biology and its impact on brain function. In-vitro diagnostics tests can offer quick, inexpensive, and reliable screening methods, further aiding in the detection and characterization of brain tumours. These advancements have facilitated more timely interventions, but innovative treatment strategies are needed to significantly impact patient outcomes.”

While surgery, chemotherapy, and radiation therapy are the standard methods of treatment, their effectiveness is often limited by factors such as tumour location and patient comorbidities. Additionally, with over 100 different types of primary brain tumour, selecting the optimal treatment approach becomes even more challenging.

Clarke continues: “Surgical removal of brain tumours requires a delicate balance between excising as much of the tumour as possible while preserving normal brain tissue. This demands a high level of skill, experience, and advanced technology, making it a costly procedure. Additionally, the increasing incidence of brain metastases, which are more common than primary brain tumours, presents additional challenges for surgical intervention.”

Emerging therapeutic modalities, such as immunotherapy and cell-targeting treatments, offer promise in the brain tumour treatment landscape. However, survival rates for patients have not improved over the past 45 years, underscoring the urgent need for increased research efforts.

Clarke concludes: “Improving the quality of life for brain tumour patients extends beyond treatment to address long-term physical and cognitive impairments. Medical devices, including neurostimulation and assistive technologies, play a crucial role in supportive care and rehabilitation services, helping survivors manage symptoms and regain independence. The future holds promise for more targeted and personalized therapies. However, it is imperative that research and awareness efforts continue to advance to meet the needs of brain tumour patients.”